https://www.yiliao.com/index.php?action=history&feed=atom&title=T670I
T670I - 版本历史
2026-04-19T08:51:56Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=T670I&diff=315597&oldid=prev
77921020：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-24T23:39:41Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>T670I</strong> 是 <strong>[[KIT]]</strong> 原癌基因酪氨酸激酶结构域第 670 位苏氨酸（Threonine）被异亮氨酸（Isoleucine）取代的错义突变。该位点位于 KIT 激酶 ATP 结合口袋的入口深处，对应于 <strong>[[14号外显子]]</strong>，被称为 KIT 激酶的“<strong>[[守门员突变]]</strong>”（Gatekeeper Mutation）。在临床上，T670I 是<strong>[[胃肠道间质瘤]]</strong>（GIST）患者接受一线药物<strong>[[伊马替尼]]</strong>治疗后常见的<strong>[[获得性耐药]]</strong>机制之一。突变引入的异亮氨酸侧链产生了空间位阻，阻止了伊马替尼的结合，但患者通常对二线药物<strong>[[舒尼替尼]]</strong>或四线药物<strong>[[瑞派替尼]]</strong>仍保持敏感。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">KIT T670I</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">GIST Gatekeeper Mutation (点击展开)</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
[[Image:KIT_T670I_mutation_structure_steric_hindrance.png|100px|T670I 突变导致的空间位阻]]<br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">GIST 二次耐药关键位点</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">所属基因</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;"><strong>[[KIT]]</strong> (c-Kit)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">外显子</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;"><strong>[[Exon 14]]</strong></td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">突变性质</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #b91c1c;"><strong>[[守门员突变]]</strong> (Gatekeeper)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">耐药药物</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #64748b;">[[伊马替尼]] (Imatinib)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">敏感药物</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #166534;"><strong>[[舒尼替尼]]</strong><br><strong>[[瑞派替尼]]</strong></td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">同源突变</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">EGFR [[T790M]]<br>ABL [[T315I]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">相关疾病</th><br />
<td style="padding: 6px 12px; color: #0f172a;">[[胃肠道间质瘤]] (GIST)</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：守门员的阻挡</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
T670I 的耐药机制是经典的“空间位阻”效应，与慢性粒细胞白血病中的 BCR-ABL T315I 突变在结构和功能上高度同源。<br />
</p><br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>守门员位置 (Gatekeeper)：</strong><br />
<br>第 670 位的苏氨酸（Thr）位于连接激酶 N 叶和 C 叶的铰链区后方，控制着通往疏水后口袋（Hydrophobic back pocket）的通道。</li><br />
<li style="margin-bottom: 12px;"><strong>位阻效应：</strong><br />
<br>伊马替尼结合 KIT 激酶时，需要深入这个疏水口袋。<br />
<br>• <strong>野生型 (T670)：</strong> 苏氨酸侧链较小，允许药物进入。<br />
<br>• <strong>突变型 (T670I)：</strong> 突变为<strong>异亮氨酸</strong>（Ile）后，侧链体积变大且疏水性增强。这不仅在物理上阻挡了伊马替尼的进入，还破坏了维持药物结合所需的关键氢键网络。</li><br />
</ul><br />
<br />
<h2 style="background: #fff1f2; color: #9f1239; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #9f1239; font-weight: bold;">临床意义：GIST 治疗的分水岭</h2><br />
<div style="background-color: #fff5f5; border-left: 5px solid #e11d48; padding: 15px 20px; margin: 20px 0; border-radius: 4px;"><br />
<h3 style="margin-top: 0; color: #be123c; font-size: 1.1em;">继发耐药的标志</h3><br />
<p style="margin-bottom: 0; text-align: justify; font-size: 0.95em; color: #334155;"><br />
T670I 几乎从不出现在原发性 GIST 中，它是在伊马替尼治疗压力下筛选出来的<strong>二次突变</strong>（Secondary Mutation）。<br />
</p><br />
</div><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.95em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">药物</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569; width: 35%;">作用机制</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af; width: 40%;">对 T670I 疗效</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;"><strong>[[伊马替尼]]</strong><br>(一线)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">II 型抑制剂 (结合非活性构象)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; color: #b91c1c;"><strong>耐药</strong></td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;"><strong>[[舒尼替尼]]</strong><br>(二线)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">多靶点 TKI</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; color: #166534;"><strong>敏感</strong><br>舒尼替尼对 ATP 结合口袋突变（如 T670I, V654A）效果较好，但对活化环突变（如 D816V）较差。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;"><strong>[[瑞派替尼]]</strong><br>(四线)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">开关控制抑制剂 (Switch-control)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; color: #166534;"><strong>敏感</strong><br>广谱抑制 KIT 原发及继发突变，包括 T670I。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">同源性对比</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
T670I 在激酶家族中具有高度的同源性，是“守门员突变”家族的一员。<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>BCR-ABL [[T315I]]：</strong> 慢粒白血病中的绝对耐药突变，需用普纳替尼或阿西米尼。</li><br />
<li style="margin-bottom: 12px;"><strong>EGFR [[T790M]]：</strong> 肺癌中导致一代药物耐药的突变，需用奥希替尼。</li><br />
<li style="margin-bottom: 12px;"><strong>PDGFRA [[T674I]]：</strong> 与 KIT T670I 位置完全对应，常见于 PDGFRA 驱动的嗜酸性粒细胞增多症。</li><br />
</ul><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Heinrich MC, Corless CL, Demetri GD, et al. (2003).</strong> <em>Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.</em> <strong>[[Journal of Clinical Oncology]]</strong>.<br><br />
<span style="color: #475569;">[基础研究]：奠基性文献，详细阐述了 GIST 中 KIT 突变的位置（包括 T670I）与药物反应之间的基因型-表型相关性。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Antonescu CR, Besmer P, Guo T, et al. (2005).</strong> <em>Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.</em> <strong>[[Clinical Cancer Research]]</strong>.<br><br />
<span style="color: #475569;">[机制发现]：通过对耐药患者的活检分析，确立了 T670I 是介导伊马替尼获得性耐药的关键二次突变之一。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[3] <strong>Smith BD, et al. (2019).</strong> <em>Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.</em> <strong>[[Cancer Cell]]</strong>.<br><br />
<span style="color: #475569;">[新药突破]：介绍了瑞派替尼的作用机制，证明其通过“开关控制”机制，能有效抑制包括 T670I 在内的多种耐药突变体。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
KIT T670I · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">突变位置</td><br />
<td style="padding: 10px 15px; color: #334155;"><strong>[[14号外显子]]</strong> (ATP结合口袋/守门员)</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">耐药对比</td><br />
<td style="padding: 10px 15px; color: #334155;">vs [[V654A]] (Exon 13) • vs [[D816V]] (活化环/难治)</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">治疗药物</td><br />
<td style="padding: 10px 15px; color: #334155;">[[舒尼替尼]] (二线) • [[瑞派替尼]] (广谱)</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">同源类比</td><br />
<td style="padding: 10px 15px; color: #334155;">EGFR [[T790M]] • ABL [[T315I]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
77921020